TABLE 2.

Typical antibodies against four pathogenic bacteria in drug development.

Antibodies	Pathogens	Targets	Company	Clinical studied	References
Raxibacumab	B. anthracis	Protective antigen	GlaxoSmith Kline	FDA approved	Subramanian et al. (2005)
Obiltoxaximab	B. anthracis	Protective antigen	Elusys Therapeutics	FDA approved	Hou and Morrill (2017)
Bezlotoxumab	C. difficile	Toxin B	Merck & Co.	Phase III	Wilcox et al. (2017)
Actoxumab	C. difficile	Toxin A	Merck & Co.	Phase III	Hernandez et al. (2017)
Panobacumab	P. aeruginosa	LPS O antigen (O11)	Kenta Biotech	Phase II/III	Lazar et al. (2009)
MEDI-3902	P. aeruginosa	PcrV type III secretion system (T3SS) and persistence factor Psl	MedImmune	Phase II	Ali et al. (2015)
Anti-pseudomonas IgY	P. aeruginosa	Immunsystem AB	Unknown	Phase I/II	Thomsen et al. (2016)
MEDI-4893	Staphylococci	Alpha toxin	MedImmune	Phase II	Yu et al. (2017)
Pagibaximab	Staphylococci	Lipoteichoic acid	Biosynexus	Phase III	Patel and Kaufman (2015)
Aurexis	Staphylococci	Clumping factor A	Bristol-Meyrs Squibb	Phase II	Weems et al. (2006)